Health Care Stocks Technical Coverage -- Research on Valeant Pharma Intl., Alkermes, Delcath Systems, and Acura Pharma

LONDON, April 9, 2014 /PRNewswire/ --

On Tuesday, April 08, 2014, the NASDAQ Composite ended at 4,112.99, up 0.81%, the Dow Jones Industrial Average edged 0.06% higher to finish the day at 16,256.14, and the S&P 500 closed at 1,851.96, up 0.38%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 659.34, down 0.80%, and the same has fallen by 3.36% in the previous three trading sessions. Investor-Edge has initiated coverage on the following equities: Valeant Pharmaceuticals International Inc. (NYSE: VRX), Alkermes PLC (NASDAQ: ALKS), Delcath Systems Inc. (NASDAQ: DCTH) and Acura Pharmaceuticals Inc. (NASDAQ: ACUR). Free technical research on VRX, ALKS, DCTH and ACUR can be downloaded upon signing up at:

http://www.investor-edge.com/937-register

Valeant Pharmaceuticals Intl. Inc.'s stock recorded a trading volume of 5.18 million shares, as compared with its three months average volume of 1.86 million shares. The stock ended the day at $122.03, up 2.35%, trading between $115.14 and $123.06. Valeant Pharmaceuticals Intl. Inc.'s shares have plummeted 5.48% in the previous three trading sessions, 13.68% in the last one month, while the same has gained 3.94% on YTD basis. The company's stock is trading above its 200-day moving average. Valeant Pharmaceuticals Intl. Inc.'s 50-day moving average of $137.97 is above its 200-day moving average of $113.69. Further, the stock has a Relative Strength Index (RSI) of 28.12. Sign up today to read free research on VRX at:

http://www.investor-edge.com/937-VRX-09Apr2014.pdf

On Tuesday, Alkermes PLC finished the session 2.38% higher at $42.08. A total of 5.17 million shares were traded, which is above its three months average volume of 1.25 million shares. The stock fluctuated between $41.82 and $45.48 during the session. The company's shares traded at a PE ratio of 154.14. Alkermes PLC's stocks have declined 5.29% in the previous three trading sessions, 9.15% in the last one month, while the same has gained 3.49% on YTD basis. The stock is trading above its 200-day moving average. Alkermes PLC's 50-day moving average of $47.82 is above its 200-day moving average of $38.68. Furthermore, the stock has an RSI of 35.56. Sign up today to read free research on ALKS at:

http://www.investor-edge.com/937-ALKS-09Apr2014.pdf

Delcath Systems Inc.'s stock reported a trading volume of 1.44 million shares, as compared with its three months average volume of 4.84 million shares. The stock ended the day at $0.29, up 0.76%, after vacillating between $0.28 and $0.31. Delcath Systems Inc.'s shares have advanced 0.83% in the previous three trading sessions and 14.71% on YTD basis, while the same has declined 11.36% in the last one month. The stock is trading below its 50-day and 200-day moving averages of $0.31 and $0.34, respectively. Additionally, the stock has an RSI of 43.97. Sign up today to read free research on DCTH at:

http://www.investor-edge.com/937-DCTH-09Apr2014.pdf

Shares in Acura Pharmaceuticals Inc. gained 2.33%, to close the day at $1.32. The stock recorded trading volume of 0.23 million shares, as compared with its three months average volume of 0.38 million shares. The stock oscillated between $1.30 and $1.38 during the trading session. Acura Pharmaceuticals Inc.'s shares have plummeted 8.97% in the previous three trading sessions, 23.70% in the last one month, and 20.96% on YTD basis. The stock is trading below its 50-day and 200-day moving averages of $1.70 and $1.73, respectively. Furthermore, the company's shares have an RSI of 26.23. Sign up today to read free research on ACUR at:

http://www.investor-edge.com/937-ACUR-09Apr2014.pdf


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-edge. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Investor-edge in this article or report according to the Procedures outlined by Investor-edge. Investor-edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Investor-edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Investor-edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

Investor-Edge.com

SOURCE Investor-Edge

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED